ClinicalTrials.gg
RecruitingNCT05796388IBSC-VRUpdated Jul 29, 2026

A Study of Virtual Reality and Linaclotide for IBS-C

An interventional study of Virtual Reality in Irritable Bowel Syndrome With Constipation, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Constipation by Mayo Clinic — 4 open to participants now, 5 under way, none of them phase 3. Constipation · Mayo Clinic.

Planned enrollment
5th of 11
65 · median 52
Started
2024
the only one that year
No phase
5 of 14
3 open now
Registered
12th of 14
by date

Among the 14 studies in Constipation by Mayo Clinic, this one is the 5th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2024, is one of 5 with no phase, and was the 12th registered.

Constipation

1,051 studies on the registry are indexed under Constipation; 163 are open to participants now.

Browse Constipation studies →

Open to participants now

4 of the 14 studies in Constipation by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Constipation by Mayo Clinic, or all of them as a file.
02

Study summary

The purpose of this study is to determine if adult patients with IBS-C will report an overall greater improvement in IBS symptoms and quality of life when treated with a combination of linaclotide (standard of care medication) and immersive virtual reality (VR) therapy compared to those treated with linaclotide and sham (placebo) VR therapy.

Read the detailed description

The primary aim of this study will be to assess the benefits of disease-targeted VR combined with linaclotide, compared to sham VR combined with linaclotide, in patients with IBS-C as defined by Rome IV criteria. The investigators hypothesize that compared to patients receiving sham VR and linaclotide, IBS-C patients receiving combination therapy with active VR and linaclotide will achieve statistically significant and clinically meaningful improvements in disease-targeted health-related quality of life while demonstrating improvements in global IBS symptoms, including abdominal pain.

Aims

  1. Evaluate changes in quality of life using the validated IBS-QoL (primary outcome);
  2. Evaluate global improvement in IBS symptoms using the validated IBS-SSS;
  3. Assess global improvement in IBS symptoms using the validated Abdominal Scoring system (11);
  4. Evaluate improvement in abdominal pain using a numerical rating system (NRS);
  5. Assess improvement in constipation using the Bristol Stool Form Scale (BSFS);
  6. Evaluate response to bloating using the validated Mayo bloating questionnaire (12);
  7. Assess response to coexisting psychological distress using the validated HADs questionnaire;
  8. Evaluate changes in work productivity using the validated WPAI.
03

Conditions studied

  • Irritable Bowel Syndrome With Constipation

Keywords

  • Virtual reality
  • IBS-C
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult men and women (18-70) who meet Rome IV criteria for IBS-C.
  • Patients will be required to score below 65 points on the IBS Quality of Life (IBS-QOL) instrument, indicating a score consistent with at least moderate HRQOL (Health-related quality of life) impairment.

Exclusion criteria

Exclusion Criteria:

  • Patients will be excluded from the study if they have a comorbid disorder that may confound the diagnosis of IBS, including celiac disease, inflammatory bowel disease, disorders that affect the GI system, history of bowel resection, /AIDS, diabetes with HgA1c >7.0, neuroendocrine tumors, microscopic colitis, lactase deficiency, eosinophilic bowel disease, acute intermittent porphyria, or any other condition that a licensed physician believes can mimic IBS symptoms and undermine diagnostic certitude.
  • Patients with severe depression, defined as a score equal to or greater than two standard deviations (SDs) on the NIH PROMIS depression scale, or those with suicidal ideations, will also be excluded and provided with standard resources to support their mental health and referred back to their primary care provider, a member of the study team will follow up with the PCP to ensure the communication was received.
  • Patients using regular doses of opioid medications will also be excluded given the often-severe impact of opioids on GI motility and potential for pharmacological visceral hyperalgesia.
  • Patients will also be excluded from the study if they do not meet Rome IV criteria for IBS-C,
  • have a known seizure disorder,
  • if symptoms are thought to represent an organic disorder,
  • if they have had prior surgery to the colon,
  • if symptoms represent a known pelvic floor disorder,
  • if the patient is abusing alcohol,
  • or if the patient cannot actively participate in the study for any other reason (e.g., inability to understand English as the VR program is in English only).
  • Patients previously treated with linaclotide who reported side effects,
  • those currently on linaclotide (any dose),
  • and those who did not note an improvement in IBS-C symptoms in the past while on linaclotide will also be excluded.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
65 participants (estimated)

Study arms

  • Sham comparator
    Sham VR

    Patients in the sham Virtual Reality group will receive the same brand of head mounted device (Oculus Quest 2), but will only have access to sham content. Both groups will receive standard of care linaclotide treatment 290 mcg.

    Device: Virtual Reality

  • Active comparator
    Immersive VR

    Patients in the immersive Virtual Reality group will receive a head mounted VR device Oculus Quest 2, and will receive active immersive content. Both groups will receive standard of care linaclotide treatment 290 mcg.

    Device: Virtual Reality

Interventions

  • DeviceVirtual Reality

    Both groups will receive standard of care linaclotide 290 mcg.

    Also known as: Linaclotide

06

What researchers measure

Primary outcomes

  1. Changes in IBS symptoms

    Measure global changes in IBS symptoms using the validated IBS severity scoring system (IBS-SSS) at week 8 compared to baseline, for patients treated with a combination of linaclotide and immersive VR and compare to those treated with linaclotide and sham VR therapy. IBS-SSS is a composite score of abdominal pain, number of days with abdominal pain, bloating/distension, satisfaction with bowel habits, and IBS-related quality of life (QoL). Each measure is rated from 0 to 100, with total scores ranging from 0 to 500. \< 175 for mild IBS, 175-300 for moderate IBS, and \> 300 for severe IBS.

    Time frame: End of study week 8 compared to baseline

Secondary outcomes

  1. Measure change in quality of life, using the validated IBS-QoL

    Irritable Bowel Syndrome-Quality of Life Measure (IBS-QOL) The individual responses to the 34 items are summed and averaged for a total score and then transformed to a 0-100 scale for ease of interpretation with higher scores indicating better IBS specific quality of life.

    Time frame: Week 8

  2. Measure changes in abdominal pain using the NRS

    The Abdominal Pain Numeric Rating Scale (NRS) patients are asked to circle the number between 0 and 10, 0 and 20 or 0 and 100 that fits best to their pain intensity. Zero usually represents 'no pain at all' whereas the upper limit represents 'the worst pain ever possible'.

    Time frame: Week 8

  3. Measure changes in bloating using the Mayo bloating questionnaire

    A 40-item questionnaire to understand the daily impact of symptoms of bloating and distension

    Time frame: week 8

  4. Measure changes in psychological distress using the HADs questionnaire;

    The Hospital Anxiety and Depression Scale (HADs) consists of 14 items and consists of two subscales: anxiety and depression. Each item is rated on a four-point scale, giving maximum scores of 21 for anxiety and depression. Scores of 11 or more on either subscale are considered to be a significant 'case' of psychological morbidity, while scores of 8-10 represents 'borderline' and 0-7 'normal'

    Time frame: week 8

  5. Measure changes in work productivity using the validated WPAI.

    The Work Productivity and Activity Impairment (WPAI) questionnaire consists of six questions: 1 = currently employed; 2 = hours missed due to health problems; 3 = hours missed other reasons; 4 = hours actually worked; 5 = degree health affected productivity while working (using a 0 to 10 Visual Analogue Scale (VAS)); 6 = degree health affected productivity in regular unpaid activities

    Time frame: Week 8

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Oct 2026, 29 months after the start.

Of 246 non-industry interventional studies with no phase under Constipation, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 35. This study's planned 29 months is above that.

Counting every sponsor, half of 317 studies reached it within 14 months; a quarter within 6 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2023
First posted
Apr 3, 2023
StartActual
May 31, 2024
Primary completionEst.
Oct 2026
CompletionEst.
Oct 2026
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05796388
Lead sponsor
Mayo Clinic
Responsible party
Brian Lacy (Professor of Medicine, Mayo Clinic) — Principal investigator
First posted
Apr 3, 2023
Start date
May 31, 2024
Primary completion
Oct 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Jul 29, 2026

Study contacts

Brian Lacy, MD, PhD
Contact
lacy.brian@mayo.edu
904-953-6970
Kristen Lozano
Contact
Lozano.Kristen@mayo.edu
904-953-4725
Brain Lacy, MD, PhD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion